{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-118342","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.344507+00:00","generated_at":"2026-05-30T00:23:20.671093+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sagimet Q3 2024 net loss $14.6M; cash $170M; denifanstat Phase 3 start expected by end of 2024","bullets":["Net loss of $14.6M for Q3 2024, vs $6.4M in Q3 2023; R&D expense increased to $12.7M.","Cash, equivalents and marketable securities of $170.0M as of Sept 30, 2024; expected to fund operations through 2025.","Denifanstat received FDA Breakthrough Therapy designation for non-cirrhotic MASH (F2/F3 fibrosis); Phase 3 program expected to initiate by end of 2024.","Phase 2b FASCINATE-2 results published in The Lancet Gastroenterology & Hepatology; end-of-Phase 2 interactions completed.","License partner Ascletis completed enrollment of 480 patients in Phase 3 acne trial in China; topline results expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-118342","json":"https://secwatch.observer/filing/0001104659-24-118342.json","markdown":"https://secwatch.observer/filing/0001104659-24-118342.md","text":"https://secwatch.observer/filing/0001104659-24-118342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/0001104659-24-118342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:23:20.671093+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}